Previous Article | Next Article ![]()
Infection and Immunity, October 1999, p. 5395-5408, Vol. 67, No. 10
Department of Microbiology and Immunology,
Chandler Medical Center, University of Kentucky, Lexington,
Kentucky 40536-0084
Received 18 February 1999/Returned for modification 2 April
1999/Accepted 6 July 1999
Yersinia pestis, the etiologic agent of plague,
secretes a set of environmentally regulated, plasmid pCD1-encoded
virulence proteins termed Yops and V antigen (LcrV) by a type III
secretion mechanism (Ysc). LcrV is a multifunctional protein that has
been shown to act at the level of secretion control by binding the Ysc
inner-gate protein LcrG and to modulate the host immune response by
altering cytokine production. LcrV also is essential for the unidirectional targeting of Yops to the cytosol of infected eukaryotic cells. In this study, we constructed an in-frame deletion within lcrG (
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Virulence Role of V Antigen of Yersinia pestis at the
Bacterial Surface

lcrG3) to further analyze the
requirement of LcrV in Yop targeting. We confirmed the essentiality of
LcrV and found that LcrG may have a facilitative role, perhaps by
promoting efficient secretion of LcrV. We also constructed mutants of
lcrV expressing LcrV truncated at the N or C terminus. Both
the N and C termini of LcrV were required for the secretion of LcrV
into the medium and targeting of Yops. LcrV was detected in punctate
zones on the surface of fixed Y. pestis by laser-scanning
confocal microscopy, and this localization required a functional Ysc.
However, the truncated LcrV proteins were not found on the bacterial
surface. Finally, we tested the ability of LcrV-specific Fab antibody
fragments or full-length antibody to interfere with Yop targeting and
found no interference, even though this antibody protects mice against plague. These results indicate that LcrV may function in Yop targeting at the extracellular surface of yersiniae and that the protective efficacy of LcrV-specific antibodies can be manifested without blocking
Yop targeting.
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, Chandler Medical Center, University of
Kentucky, Lexington, KY 40536-0084. Phone: (606) 323-6538. Fax: (606)
257-8994. E-mail: scstra01{at}pop.uky.edu.
Present address: Department of Microbiology and Immunology,
University of North Dakota, Grand Forks, ND 58202.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|